U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07369622) titled 'HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness' on Jan. 18.
Brief Summary: Severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS), are rare but life-threatening complications that can occur after starting allopurinol for gout. The HLA-B58:01 allele is a strong genetic risk factor for allopurinol-associated SCARs in Asian populations. This study evaluates the feasibility and clinical value of HLA-B58:01 screening before first-time allopurinol use in Vietnamese adults with gou...